Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: Are we really making steps forward?

Maristella Bianconi, Luca Faloppi, Michele Del Prete, Riccardo Giampieri, Alessandro Bittoni, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Mario Scartozzi, Stefano Cascinu, Rodolfo Montironi

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.

Original languageEnglish (US)
Pages (from-to)3-13
Number of pages11
JournalAnalytical and Quantitative Cytology and Histology
Volume37
Issue number1
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Angiogenesis inhibitors
  • C-reactive protein
  • Cancer treatment protocols
  • Leukocytes
  • Leukopenia
  • Neutrophils
  • Renal cell carcinoma
  • Sunitinib
  • Treatment
  • Tumor markers

ASJC Scopus subject areas

  • Anatomy
  • Histology
  • Medicine(all)

Cite this

Bianconi, M., Faloppi, L., Prete, M. D., Giampieri, R., Bittoni, A., Lopez-Beltran, A., Scarpelli, M., Cheng, L., Scartozzi, M., Cascinu, S., & Montironi, R. (2015). Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: Are we really making steps forward? Analytical and Quantitative Cytology and Histology, 37(1), 3-13.